Two Sigma Advisers
VYNE icon

Two Sigma Advisers’s VYNE Therapeutics VYNE Stock Holding History

Two Sigma Advisers’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-163,100
Closed -$94.6K – 2129
2025
Q4 		$94.6K Buy
163,100
+106,500
+188% +$42.7K ﹤0.01% 2232
2025
Q3 		$19K Buy
+56,600
New +$37K ﹤0.01% 2303
2021
Q3 		– Sell
-2,467
Closed -$156K – 2695
2021
Q2 		$156K Sell
2,467
-10,241
-81% -$811K ﹤0.01% 2297
2021
Q1 		$1.57M Buy
12,708
+6,191
+95% +$898K ﹤0.01% 1395
2020
Q4 		$741K Buy
6,517
+3,636
+126% +$457K ﹤0.01% 1707
2020
Q3 		$344K Buy
2,881
+809
+39% +$94.4K ﹤0.01% 1962
2020
Q2 		$258K Buy
2,072
+1,789
+632% +$242K ﹤0.01% 2178
2020
Q1 		$55K Sell
283
-131
-32% -$41.1K ﹤0.01% 2370
2019
Q4 		$138K Sell
414
-18
-4% -$6K ﹤0.01% 2233
2019
Q3 		$139K Buy
432
+7
+2% +$2.26K ﹤0.01% 2085
2019
Q2 		$183K Buy
425
+33
+8% +$16.3K ﹤0.01% 2147
2019
Q1 		$221K Buy
392
+150
+62% +$72K ﹤0.01% 2091
2018
Q4 		$72K Buy
242
+20
+9% +$8.95K ﹤0.01% 2251
2018
Q3 		$158K Buy
+222
New +$137K ﹤0.01% 2116

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers's VYNE Position: Q1 2026 in Review

Two Sigma Advisers sold out of VYNE Therapeutics (VYNE) in Q1 2026, closing a stake of 163,100 shares — an estimated $94.6K sold.

Two Sigma Advisers first reported a position in VYNE in Q3 2018 and held it in 14 quarters. The position peaked at $1.57M in Q1 2021. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Two Sigma Advisers reported no remaining VYNE Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 163,100 VYNE Therapeutics shares in Q1 2026, an estimated $94.6K.
  • Two Sigma Advisers first reported a position in VYNE Therapeutics in Q3 2018 and held it in 14 quarters.
  • Two Sigma Advisers's VYNE Therapeutics position peaked at $1.57M in Q1 2021.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.